4.5 Editorial Material

A Refined Developability Classification System

期刊

JOURNAL OF PHARMACEUTICAL SCIENCES
卷 107, 期 8, 页码 2020-2032

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.xphs.2018.03.030

关键词

dissolution; high throughput technology(s); oral absorption; Biopharmaceutics Classification System (BCS); formulation in vitro model(s); permeation enhancers(s); solubility; supersaturation

资金

  1. Innovative Medicines Initiative Joint Undertaking [115369]
  2. European Union's Seventh Framework Programme (FP7/2007-2013)
  3. EFPIA

向作者/读者索取更多资源

In 2010, the Developability Classification System (DCS) was proposed. The DCS was designed to close the gap between the biopharmaceutics classification system, which is aimed at guiding regulatory decisions about well-characterized drugs, and the need for early evaluation of drug candidates with respect to their suitability for oral delivery. The DCS applied solubility in fasted state simulated intestinal fluid to estimate intestinal solubility, assessed the compensatory nature of permeability and solubility during oral absorption and provided a way of estimating the critical the particle size at which dissolution becomes rate-limiting to absorption. Building on this framework, a refined developability classification system (rDCS) is now proposed. The rDCS is stratified into standard investigations applied to all candidates, and customized investigations. Standard investigation of solubility and permeability can be performed according to in-house methods, and the results compared with standard data sets of fasted state human intestinal fluid solubility and human effective jejunal permeability, which have been generated specifically for rDCS. Customized investigations are triggered when there is potential for supersaturation/ precipitation (weak bases; salts of weak acids) and to assess dissolution versus permeation limited absorption. In addition, the rDCS offers facile visualization of the results, enabling pragmatic comparison of drug candidates and formulation approaches. (C) 2018 Published by Elsevier Inc. on behalf of the American Pharmacists Association.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据